CELLCEPT (mycophenolate mofetil hydrochloride) by Roche is (mmf) is absorbed following oral administration and hydrolyzed to mycophenolic acid (mpa), the active metabolite. First approved in 1998.
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
CellCept (mycophenolate mofetil HCl) is an oral immunosuppressant that selectively inhibits inosine monophosphate dehydrogenase (IMPDH), blocking de novo guanosine nucleotide synthesis in lymphocytes. It is used to prevent organ transplant rejection by suppressing T- and B-cell proliferation and reducing pro-inflammatory cytokine production. The drug works through a reversible, cytostatic mechanism that shifts lymphocyte metabolism from proliferative to catabolic states.
Product is in late-stage lifecycle with LOE approaching, signaling consolidation or transition focus for smaller brand teams.
(MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the de novo pathway of…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on CELLCEPT at Roche? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant Recipients
An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients
A Pharmacokinetic Study of CellCept (Mycophenolate Mofetil) Versus Mycophenolate Sodium in Kidney Transplant Patients
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on CellCept offers deep expertise in transplant immunology and specialty care commercialization, but limited upside growth due to LOE proximity and mature indication. Roles focus on defending market share, maintaining relationships with transplant centers, and navigating generic competition rather than driving new patient populations.